Bioresorbable Scaffolds Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The global bioresorbable scaffolds market generated remarkable revenue in 2024 and is expected to grow at a notable CAGR during 2025-2034 driven by the rising prevalence of cardiovascular diseases, predominantly coronary artery disease (CAD). As per WHO, cardiovascular diseases (CVDs) remained the foremost cause of death worldwide, accounting for approximately 17.9 million fatalities annually. Coronary artery disease continues to be a leading cause of death worldwide, creating an increased need for innovative medical devices aimed at reducing long-term complications.
Bioresorbable scaffolds can provide extra support for the artery as it heals and can be organically degraded - which is a fast-growing appreciation. With a bioresorbable scaffold, one can hypothetically eliminate any risk imposed by leaving a permanent material (i.e. stent) and late stent thrombosis and/or restenosis can be avoided.
The increased adoption of bioresorbable scaffolds is also fueled by advances in materials science that have driven innovation and improvement in the durability and efficacy of devices. As clinical studies continue to emerge, outcomes have indicated bioresorbable scaffolds may potentially deliver superior patient outcomes than a stent, supporting increasing demand from patients and healthcare entities.
Furthermore, the increased prevalence of minimally invasive procedures and the sustained demand for long-term devices that enhance the quality of life for patients are propelling the bioresorbable scaffolds market forward. Drug-eluting scaffolds can aid in addressing long-term concerns for patients and deliver additional benefits such as controlled delivery of anti-proliferative drugs in efforts to improve patient outcomes providing a delay of restenosis acquiescence.
As more healthcare professionals recognize the advantages presented by bioresorbable scaffolds in comparison with traditional metallic stents, there is an increasing shift from the use of metallic stents to bioresorbable scaffolds. Bioresorbable scaffolds have exhibited favorable clinical results insofar as long-term complications like in-stent restenosis and thrombosis have been considerably reduced. Additionally, the advancement of the completely drug-eluting bioresorbable scaffold has been marked as one of the biggest reasons for the growth of the market.
Drug-eluting bioresorbable scaffolds create structural support after deployment and release anti-proliferative drugs to limit the development of in-stent restenosis, which is one of the most frequent complications associated with coronary artery stenting. Thus, scaffold structure support and controlled release of drugs have enhanced demand. The high cost of bioresorbable scaffolds is also expected to limit market growth, specifically, their low mechanical properties including low radial strength when compared to metallic stents. Although the bioresorbable scaffold durability needs to be further developed, the devices must overcome strict steps to gain approval for regulatory review.
The market is currently undergoing some important trends that will shape its future. One of the most important trends is based on the development of bioresorbable scaffolds with improved material properties to enhance both their degradation rate and mechanical properties. The effort that researchers have undertaken is to improve the materials used in bioresorbable scaffolds such as poly-L-lactic acid (PLLA) and biodegradable magnesium alloys that have better durability and ensure they are completely reabsorbed after use.
This development is significant because the initial failure of bioresorbable scaffolds was because they are mechanically weaker than metallic stents. Another trend is the use of drug-eluting bioresorbable scaffolds. As drug-eluting stents (DES) became a gold standard for coronary interventions, the use of drug-eluting bioresorbable scaffolds is becoming more common. A drug-eluting bioresorbable scaffold is a device that delivers a sustained release of anti-proliferative drugs to discourage local reparative responses to injury and can limit the occurrences of restenosis. The trend of minimally invasive surgery has also affected the growth of bioresorbable scaffolds.
The drug-eluting bioresorbable coronary scaffolds segment held a notable share in 2024. DEBCSs can provide structural support, like traditional stents, while also permitting drug release to impede the growth of arterial tissue causing restenosis. Besides their structural support, drug-eluting bioresorbable coronary scaffolds differ from traditional drug-eluting stents (DES), which are made from permanent metal. Bioresorbable scaffolds are intended to dissolve over time after use, reducing a patient's risk for long-term complications and future interventions.
The clinical trial data supporting the numerous advantages of drug-eluting bioresorbable scaffolds (DEBCSs) as compared to metallic scaffolds is increasing annually, driving the need for implantation and subsequent clinical scenarios that help reduce restenosis and improve long-term patient outcomes. Additionally, DEBCS's unique advantage of being suitable for a more extensive patient population could benefit from using DEBCS, including patients with complex coronary anatomy due to favorable material properties. The pace of innovation in terms of materials that offer specific stiffness and faster degradation profiles such as poly-L-lactic acid (PLLA) and magnesium alloys propel market growth.
The hospitals segment from the bioresorbable scaffolds market held the largest share in 2024 as hospitals are the main healthcare providers for patients who suffer from coronary artery disease. In coronary artery procedures, hospitals have offered more advanced cardiac care units to increase the uptake rate of bioresorbable scaffolds. Hospitals with PCI capabilities could be an indicator of bioresorbable scaffold usage as the amount of PCI patients continues to rise.
Hospitals allow for more complex treatment procedures, such as CABG or Angioplasty, or procedures in conjunction with others like bioresorbable scaffolds, to start to implement it in their treatment plans. Hospitals are better facilitated to ensure proper disaster follow-up care is evaluated after bioresorbable scaffold implantation. This is important because continuity of care is a necessity for successful evaluations and ultimately success with the implant once it is bioresorbable scaffolds are implanted.
North America bioresorbable scaffolds market generated notable revenues in 2024. As a result of a high burden of cardiovascular diseases, robust healthcare infrastructure, and a culture of minimally invasive procedures, it contributes to bioresorbable scaffolds trending upward in this region. A rising number of coronary artery disease cases with an increasing older population have the potential to develop the demand for new products bioresorbable scaffolds as an alternative to coronary stents.
Healthcare providers in North America continue to adopt advanced technologies to improve patient outcomes and lessen the likelihood associated with coronary artery disease. Indeed, new product developments clinically and new product approvals are propelling the industry and will only provide additional pathways to new bioresorbable scaffold product approvals. North America fuels market growth, as there are established R&D capabilities at scale to support continuous product development and key players in the business of bioresorbable scaffolds.
Notable players in the bioresorbable scaffolds industry include:
To establish and strengthen the market presence and space, leading companies have implemented a variety of techniques. One typical strategy is continuously developing research and development (R&D) to build on and create new materials and improve scaffold performance. This process improves strength and degradation rates for bioresorbable scaffolds enabling companies to provide scaffolds that could be used safely for longer periods of time, with elite performance in restoring surfaces to their normal function or original anatomy.
Strategic partnerships, collaborations with academic institutions & hospitals, and hands-on experience with markets are important for the development of companies involved in the market space. Partnerships keep companies relevant when they can test the durability of products and offer a platform that assists in testing clinical trials, offering acceptance based on sending samples for regulatory approval to bring new products to the market. In addition, companies are refining their strategic plans by upgrading product portfolios with different countries or emerging regions with developing markets.
In April 2024, Abbott re-entered the field of bio-absorbable, dissolving stents, venturing into relatively new territory. It had secured a groundbreaking approval from the FDA for its newest drug-eluting scaffold, which was developed to treat blocked arteries located below the knee.